Value of treatment in clinical trials versus the real world: the case of abiraterone acetate (Zytiga) for postchemotherapy metastatic castration-resistant prostate cancer patients in Sweden.

Title : Value of treatment in clinical trials versus the real world: the case of abiraterone acetate (Zytiga) for postchemotherapy metastatic castration-resistant prostate cancer patients in Sweden

Source : PubMed
ID : 27109827
Authors : Svensson J, Andersson E, Persson U, Edekling T, Ovanfors A, Ahlgren G
Year : 2016
Disease Category : Cancer
Focused Population : Not Specified
Priori/Posteriori : Posteriori
Single-study Generalibility? : Single
Score/Non-Score : Non-score
Tutorial/Method : NHANES_T2D
Compared general demographic and patient characteristics : Yes
Compared disease-specific clinical characteristics : Yes
Compared adverse events : No
Compared outcomes/treatment effect (including survival) : Yes
Trial participants vs. general population (from EHR, survey, a cohort, etc) : Yes
Real-world data sources : December 2013 at the urological clinics of Skånes University Hospital (SUS, Malm€o) and Blekingesjukhuset (Karlskrona), and between June and July 2014 at Uppsala University Hospital
Target Population Data Type Levels : Hospital